Analyst Conference Summaries

Biotechnology Investor Aids

Seattle Genetics
SGEN

conference date: October 26, 2017 @ 1:30 PM Pacific Time

AML Therapies: Seattle Genetics vs. GlycoMimetics [July 15, 2016 at Seeking Alpha]

Seattle Genetics: The Long View [February 25, 2015 at SeekingAlpha]

2017
 
April 27, 2017
July 27, 2017
Oct. 26, 2017
 
2016
04/28/2016
07/26/2016
10/27/2016
02/09/2017
2015
04/30/2015
07/30/2015
10/29/2015
02/09/2016
2014
not available
07/31/2014
10/30/2014
02/10/2015

Seattle Genetics develops antibody-based therapies for cancer. Adcetris is its first commercially approved therapy.

Seattle Genetics web site
Seattle Genetics investor relations page


 

Search

More Analyst Conference Pages:

 AGEN
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 CELG
 GILD
 INTC
 INO
 ISRG
 MCHP
 MYL
 NVDA
 REGN
 VRTX
 XLNX

 
 

Disclaimer: Our analyst summaries may include both our condensations of statements made by company representatives and our own analysis. They are not covered by any warranty. We cannot guarantee anything said by company representatives is true. We try not to make errors, but it is possible. Before making or terminating an investment you should always verify any factual basis of your decision.

Copyright 2017 William P. Meyers